Natalizumab, which binds very late antigen-4 (VLA-4), is a potent therapy for multiple sclerosis (MS). Studies have focused primarily upon its capacity to interfere with T-cell migration into the central nervous system (CNS). B cells are important in MS pathogenesis and express high levels of VLA-4. Here, we report that the selective inhibition of VLA-4 expression on B cells impedes CNS accumulation of B cells, and recruitment of Th17 cells and macrophages, and reduces susceptibility to experimental autoimmune encephalomyelitis. These results underscore the importance of B-cell VLA-4 expression in the pathogenesis of CNS autoimmunity and provide insight regarding mechanisms that may contribute to the benefit of natalizumab in MS, as well as candidate therapeutics that selectively target B cells. ANN NEUROL 2015; 77:902-908 N atalizumab, a monoclonal antibody (mAb) directed against the human a4 (CD49d) subunit of the integrin very late antigen-4 (VLA-4), is a potent treatment for relapsing-remitting multiple sclerosis (RRMS). 1 Studies of anti-VLA-4 treatment in experimental autoimmune encephalomyelitis (EAE), considered predominantly a T-cell-mediated disease, indicate that its effects on T cells, [2] [3] [4] in particular Th1 cells, 5 are responsible for the clinical benefit of natalizumab. The recent successful use of anti-CD20 B-cell-depleting agents in multiple sclerosis (MS) treatment trials 6 has renewed appreciation for the role of B cells in MS pathogenesis and interest in evaluating their response to MS therapeutics. Although VLA-4 is more highly expressed on the surface of mature B cells than on T cells, 7 less is known regarding the influence of anti-VLA-4 therapy on B cells than on T cells. One in vitro study suggested that engagement of VLA-4 on B cells with its endothelial ligand VCAM-1 is required for their migration across the blood-brain barrier (BBB). 8 In this regard, natalizumab treatment of MS has been associated with elevation of B cells in peripheral blood 9 and reduction in cerebrospinal fluid. 10 Thus, given these observations and the recent increased appreciation for the role of B cells in MS and EAE, 6, [11] [12] [13] we questioned whether the clinical benefit of anti-VLA-4 therapy could also relate to its potential influence on B-cell trafficking into the CNS. 
Materials and Methods

Cell Isolation
Blood was collected via cardiac puncture. After erythrocyte lysis, leukocytes were washed. Spleen and CNS mononuclear cells were isolated after perfusion with phosphate-buffered saline (PBS).
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Flow Cytometric Analysis
Antimouse FcRIIB/FcRIIIA mAb (2.4G2; BD, Franklin Lakes, NJ) was used to avoid nonspecific staining. Aqua dead cell stain kit was used for live/dead cell separation and CountBright counting beads (both Molecular Probes, Eugene, OR) for absolute cell number quantification. Antibodies to mouse CD19 PerCP-Cy5.5 (eBio1D3), B220 (CD45R) APC-Cy7 (RA3-6B2), MHC-II (I-A/I-E) PE-Cy7 (M5/114.15.2), CD80 (B7-1) APC (16-10A1), CD4 APC-Cy7 (RM4-5), and CD11b PECy7 (M1/70) were purchased from eBioscience (San Diego, CA). Antibodies to B220 (CD45R) FITC (RA3-6B2), CD45 APC (30-F11), and CD49d PE (9C10) were purchased from BD. An isotype-and fluorochrome-matched control antibody (IgG2a kappa PE; R35-95; BD) was used to assess nonspecific staining for CD49d. Analysis was performed on a BD LRSFortessa flow cytometer using FACSDiva software (BD).
Intracellular Cytokine Staining
Intracellular cytokine staining (ICS) was performed as described, 12 using aqua dead cell stain kit (Molecular Probes) and antibodies to CD4 PE-Cy7 (RM4-5), IL-17A PerCPCy5.5 (eBio17B7), and IFN-c APC (XMG1.2; all eBioscience).
Detection of Anti-MOG Antibodies
Anti-rhMOG immunoglobulin G (IgG) was measured with a noncommercial enzyme-linked immunosorbent assay as described, 12 using rhMOG and horseradish peroxidase-labeled goat antimouse IgG (Thermo Scientific, Waltham, MA).
Immunohistochemistry
Mice were perfused with PBS followed by 10% formalin for fixation. Brains and spinal cords were dissected, paraffinembedded, and sectioned. Immunohistochemical staining (CD3 and B220) and hematoxylin counterstaining were performed on representative sections. 12 Meningeal and parenchymal B220 1 B cells and CD3 1 T cells were counted by a blinded observer (R.A.S.).
Statistical Analysis
Mann-Whitney U test was used for clinical scores. All other statistical analysis was performed using an unpaired t test. A value of p 0.05 was considered significant.
Results
In this investigation, EAE was induced by rhMOG, which requires the participation of both T and B cells.
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Administration of anti-a4 mAb ameliorated EAE induced by rhMOG protein in C57BL/6 wild-type mice (see Fig  1) . To investigate the role of VLA-4 expression on B cells in EAE pathogenesis, we created mice (CD19cre/a4 f/f ) that selectively lack B-cell a4 expression by crossing the CD19cre knockin, which selectively directs gene expression in B cells, but not in T cells or in other leukocytes, 15 (and data not shown) onto the a4 f/f background.
VLA-4 was not detected on B cells from naive CD19cre/ a4 f/f mice, whereas CD4 1 T cells expressed normal levels (Fig 2A) . Similar results were observed in the blood and spleen of rhMOG-immunized mice (data not shown). In comparison to either CD19cre/a4 f/WT or CD19cre control mice, CD19cre/a4 f/f mice exhibited a reduction in EAE susceptibility, which was most pronounced at the peak of disease (see Fig 2B) . Similar results were observed in an independent experiment using a4 f/f mice as control group (data not shown).
Although VLA-4 is recognized primarily for its role in endothelial transmigration of leukocytes, the interaction of VLA-4 with its receptor, VCAM-1, can also mediate costimulation. 16 Therefore, selective elimination of B-cell VLA-4 expression could conceivably alter EAE susceptibility via its influence on peripheral immune responses and/or CNS B-cell migration. First, in comparison between control and CD19cre/a4 f/f mice with EAE, there were no evident differences in peripheral B-cell activation as measured by expression of CD80 or MHC II (see Fig 2C) . Second, there were no significant differences in peripheral numbers of Th1 and Th17 cells, indicating that selective elimination of B-cell VLA-4 expression did not alter in vivo antigen presentation by B cells or other antigen-presenting cells (see Fig 2D) . Lastly, as immunization with rhMOG protein can elicit secretion of pathogenic (demyelinating) antibodies, 17 we examined MOG-specific antibodies in control and CD19cre/a4 f/f mice with rhMOG-induced EAE. No significant differences in anti-rhMOG IgG titers were observed (see Fig  2E) . By these measures, selective elimination of VLA-4 expression did not significantly influence proinflammatory peripheral B-cell function. Our observation that selective B-cell VLA-4 deficiency reduced EAE susceptibility, but did not impact peripheral immune responses, indicates its primary effect may be attributed to its influence on B-cell migration. Flow cytometric analysis revealed a significant reduction in absolute numbers of CNS-infiltrating CD19
f/f mice (Fig 3A) , findings that were confirmed by immunohistological staining. Reduction of B220 1 (CD45R 1 ) B cells was most pronounced in the meninges, which contained the majority of CNSinfiltrating B cells in control mice with EAE (see Fig  3B) . There were no clearly detectable differences in the histological appearances of microglia or astrocytes in lesions in CD19cre/a4 f/f and control mice with EAE. 
CD4
1 T cells (see Fig   3C-E) . Similarly, meningeal CD3 1 T cells were reduced in CD19cre/a4 f/f mice, as measured by immunohistochemistry (see Fig 3B) . Moreover, the frequency of Th17 but not Th1 cells was significantly reduced in the CNS of CD19cre/a4
f/f mice with EAE (see Fig 3F) . In summary, our results indicate that conditional B-cell VLA-4 deficiency inhibited CNS Bcell accumulation, reduced recruitment of other effector leukocytes, and suppressed development of EAE.
Discussion
Since 1992, when it was reported that anti-VLA-4 antibody treatment could prevent EAE, 4 providing the foundation for advancing development of natalizumab in MS, Although effective in MS, natalizumab has exacerbated neuromyelitis optica (NMO). 19 There may be several contributing factors. First, NMO is a humoral autoimmune disease that is associated with aquaporin-4 (AQP4)-specific antibodies, which are generated primarily outside of the CNS. We observed that B-cell VLA-4 deficiency did not influence peripheral humoral responses. Second, neutrophils are abundant in NMO lesions 20 and are thought to contribute to NMO pathogenesis. Th17 cells can promote CNS neutrophil accumulation, 21 and AQP4-specific T cells in NMO exhibit Th17 polarization. 22 Third, as resting human neutrophils do not express VLA-4, 23 CNS migration of this leukocyte subset may be unopposed by natalizumab. Thus, one can speculate that natalizumab treatment, which may be less effective in Th17-mediated CNS disease, 5 could facilitate CNS neutrophil accumulation in NMO.
Possibly the most important observation in our study is that selective B-cell VLA-4 deficiency was associated with reduced CNS recruitment of other effector cells. This finding may be particularly relevant to therapies that selectively target B cells. In this regard, despite knowledge that B cells constitute a minority of infiltrating cells in characteristic lesions of RRMS, 24 B-cell depletion in RRMS results in a marked reduction in gadolinium-enhancing CNS lesions. 6 Anti-CD20 B-cell depletion in EAE significantly reduces meningeal B cells.
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Similarly, the observation that selective B-cell VLA-4 deficiency not only inhibited accumulation of meningeal B cells, but also reduced CNS recruitment of other leukocytes, may provide an additional mechanism for reduction in CNS inflammatory lesions by therapies that eliminate B cells. Our study, which highlights the importance of VLA-4 on B cells in the pathogenesis of CNS autoimmunity, should promote investigations to further understand how CNS B cells influence cellular immune responses in situ.
